AN2 Therapeutics Inc (NASDAQ: ANTX)’s stock price has dropped by -12.40 in relation to previous closing price of 1.21. Nevertheless, the company has seen a loss of -10.92% in its stock price over the last five trading days. businesswire.com reported 2025-05-29 that MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that.
Is It Worth Investing in AN2 Therapeutics Inc (NASDAQ: ANTX) Right Now?
Company’s 36-month beta value is -0.01.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for ANTX is 19.90M, and currently, short sellers hold a 0.21% ratio of that floaft. The average trading volume of ANTX on June 02, 2025 was 146.32K shares.
ANTX’s Market Performance
ANTX’s stock has seen a -10.92% decrease for the week, with a -14.52% drop in the past month and a -7.02% fall in the past quarter. The volatility ratio for the week is 7.83%, and the volatility levels for the past 30 days are at 4.03% for AN2 Therapeutics Inc The simple moving average for the past 20 days is -10.70% for ANTX’s stock, with a -12.14% simple moving average for the past 200 days.
Analysts’ Opinion of ANTX
Many brokerage firms have already submitted their reports for ANTX stocks, with Leerink Partners repeating the rating for ANTX by listing it as a “Market Perform.” The predicted price for ANTX in the upcoming period, according to Leerink Partners is $1 based on the research report published on August 09, 2024 of the previous year 2024.
Leerink Partners gave a rating of “Outperform” to ANTX, setting the target price at $5 in the report published on July 03rd of the previous year.
ANTX Trading at -16.58% from the 50-Day Moving Average
After a stumble in the market that brought ANTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.47% of loss for the given period.
Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 7.83%, as shares sank -14.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.40% lower at present.
During the last 5 trading sessions, ANTX fell by -10.92%, which changed the moving average for the period of 200-days by +2.91% in comparison to the 20-day moving average, which settled at $1.1870. In addition, AN2 Therapeutics Inc saw -23.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANTX starting from Leonard Braden Michael, who sale 2,100,000 shares at the price of $1.16 back on May 28 ’25. After this action, Leonard Braden Michael now owns 3,649,432 shares of AN2 Therapeutics Inc, valued at $2,436,000 using the latest closing price.
Leonard Braden Michael, the 10% Owner of AN2 Therapeutics Inc, sale 432,000 shares at $1.01 during a trade that took place back on May 30 ’25, which means that Leonard Braden Michael is holding 3,217,432 shares at $436,477 based on the most recent closing price.
Stock Fundamentals for ANTX
The total capital return value is set at -0.68. Equity return is now at value -49.32, with -44.77 for asset returns.
Currently, EBITDA for the company is -51.32 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.68.
Conclusion
In a nutshell, AN2 Therapeutics Inc (ANTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
